A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
← catalyst calendarNCT06043700 · readout in 590 d
Sponsored by Eisai Limited (industry) · 4523.T — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-12 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Disease
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Low, Medium, and High Amyloid Pathology
measured At Screening on Day 1
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed